Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva b.v., holandsko - iné antiinfektíva - 64 - ophthalmologica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - dexametazón a antiinfektíva - 64 - ophthalmologica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - dexametazón a antiinfektíva - 64 - ophthalmologica

Unión Europea - eslovaco - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - eslovaco - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - eslovaco - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - eslovaco - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologiká - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

adamed pharma s.a., poľsko - hymekromón - 43 - choleretica, cholekinetica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - ciprofloxacín - 42 - chemotherapeutica (vratane tuberkulostatik)

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - ciprofloxacín - 42 - chemotherapeutica (vratane tuberkulostatik)